GlucoTrack, Inc. (GCTK)
USD 0.36
(-7.29%)
USD 0.36
(-7.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.09 Million USD | -59.91% |
| 2022 | -4.43 Million USD | -8.24% |
| 2021 | -4.1 Million USD | -57.81% |
| 2020 | -2.59 Million USD | 26.11% |
| 2019 | -3.51 Million USD | 47.64% |
| 2018 | -6.71 Million USD | 34.98% |
| 2017 | -10.32 Million USD | -90.93% |
| 2016 | -5.4 Million USD | 7.4% |
| 2015 | -5.84 Million USD | -296.02% |
| 2014 | 2.98 Million USD | 130.42% |
| 2013 | -9.79 Million USD | -253.38% |
| 2012 | -2.77 Million USD | -17.26% |
| 2011 | -2.36 Million USD | 15.21% |
| 2010 | -2.78 Million USD | -131.93% |
| 2009 | -1.2 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.48 Million USD | -53.37% |
| 2024 Q1 | -2.92 Million USD | -21.35% |
| 2023 Q1 | -1.28 Million USD | -0.31% |
| 2023 Q4 | -2.41 Million USD | -208.5% |
| 2023 FY | -7.09 Million USD | -59.91% |
| 2023 Q3 | 2.22 Million USD | 289.03% |
| 2023 Q2 | -1.17 Million USD | 8.7% |
| 2022 Q1 | -1.09 Million USD | 27.42% |
| 2022 Q4 | -1.28 Million USD | -38.51% |
| 2022 Q3 | -927 Thousand USD | 18.04% |
| 2022 FY | -4.43 Million USD | -8.24% |
| 2022 Q2 | -1.13 Million USD | -3.48% |
| 2021 FY | -4.1 Million USD | -57.81% |
| 2021 Q2 | -853 Thousand USD | 5.64% |
| 2021 Q3 | -804 Thousand USD | 5.74% |
| 2021 Q4 | -1.5 Million USD | -87.31% |
| 2021 Q1 | -904 Thousand USD | -2.84% |
| 2020 Q4 | -879.04 Thousand USD | -72.69% |
| 2020 Q2 | -574.17 Thousand USD | 21.75% |
| 2020 Q1 | -733.76 Thousand USD | -22.53% |
| 2020 Q3 | -509.01 Thousand USD | 11.35% |
| 2020 FY | -2.59 Million USD | 26.11% |
| 2019 Q4 | -598.85 Thousand USD | 39.92% |
| 2019 Q2 | -898.85 Thousand USD | 12.02% |
| 2019 Q3 | -996.77 Thousand USD | -10.89% |
| 2019 Q1 | -1.02 Million USD | 23.31% |
| 2019 FY | -3.51 Million USD | 47.64% |
| 2018 Q3 | -1.57 Million USD | 19.85% |
| 2018 FY | -6.71 Million USD | 34.98% |
| 2018 Q4 | -1.33 Million USD | 15.3% |
| 2018 Q2 | -1.96 Million USD | -6.21% |
| 2018 Q1 | -1.84 Million USD | 30.44% |
| 2017 FY | -10.32 Million USD | -90.93% |
| 2017 Q4 | -2.65 Million USD | -2.78% |
| 2017 Q1 | -2.53 Million USD | -122.11% |
| 2017 Q2 | -2.55 Million USD | -1.06% |
| 2017 Q3 | -2.58 Million USD | -1.08% |
| 2016 Q1 | -1.22 Million USD | 20.59% |
| 2016 Q2 | -1.58 Million USD | -29.53% |
| 2016 FY | -5.4 Million USD | 7.4% |
| 2016 Q4 | -1.13 Million USD | 21.69% |
| 2016 Q3 | -1.45 Million USD | 8.45% |
| 2015 Q1 | -1.53 Million USD | -98.0% |
| 2015 Q3 | -1.09 Million USD | 34.25% |
| 2015 Q4 | -1.54 Million USD | -40.96% |
| 2015 Q2 | -1.66 Million USD | -8.62% |
| 2015 FY | -5.84 Million USD | -296.02% |
| 2014 Q4 | -775.01 Thousand USD | -0.71% |
| 2014 Q3 | -769.57 Thousand USD | -114.63% |
| 2014 Q2 | 5.26 Million USD | 814.04% |
| 2014 Q1 | -736.91 Thousand USD | 89.73% |
| 2014 FY | 2.98 Million USD | 130.42% |
| 2013 Q3 | -699.86 Thousand USD | -21.38% |
| 2013 Q4 | -7.17 Million USD | -925.45% |
| 2013 FY | -9.79 Million USD | -253.38% |
| 2013 Q1 | -1.34 Million USD | -92.12% |
| 2013 Q2 | -576.59 Thousand USD | 57.09% |
| 2012 Q2 | -737.45 Thousand USD | -16.14% |
| 2012 Q1 | -634.95 Thousand USD | -6.05% |
| 2012 FY | -2.77 Million USD | -17.26% |
| 2012 Q4 | -699.34 Thousand USD | 0.17% |
| 2012 Q3 | -700.55 Thousand USD | 5.0% |
| 2011 Q2 | -516.65 Thousand USD | 4.37% |
| 2011 Q4 | -598.71 Thousand USD | 15.52% |
| 2011 Q3 | -708.7 Thousand USD | -37.17% |
| 2011 Q1 | -540.26 Thousand USD | 0.0% |
| 2011 FY | -2.36 Million USD | 15.21% |
| 2010 FY | -2.78 Million USD | -131.93% |
| 2009 FY | -1.2 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -63.32 Million USD | 88.792% |
| AngioDynamics, Inc. | -184.34 Million USD | 96.15% |
| AtriCure, Inc. | -30.43 Million USD | 76.684% |
| Avinger, Inc. | -18.32 Million USD | 61.261% |
| Azenta, Inc. | -14.25 Million USD | 50.221% |
| BioLife Solutions, Inc. | -66.42 Million USD | 89.316% |
| The Cooper Companies, Inc. | 294.2 Million USD | 102.412% |
| Daxor Corporation | 280.64 Thousand USD | 2628.863% |
| Ekso Bionics Holdings, Inc. | -15.19 Million USD | 53.303% |
| Femasys Inc. | -14.24 Million USD | 50.186% |
| Harvard Bioscience, Inc. | -3.41 Million USD | -107.818% |
| Hologic, Inc. | 789.5 Million USD | 100.899% |
| ICU Medical, Inc. | -29.65 Million USD | 76.068% |
| Intuitive Surgical, Inc. | 1.79 Billion USD | 100.395% |
| KORU Medical Systems, Inc. | -13.74 Million USD | 48.352% |
| LeMaitre Vascular, Inc. | 30.1 Million USD | 123.574% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -6.507% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -6.507% |
| Masimo Corporation | 81.5 Million USD | 108.708% |
| Microbot Medical Inc. | -10.74 Million USD | 33.92% |
| Meihua International Medical Technologies Co., Ltd. | 11.62 Million USD | 161.047% |
| Merit Medical Systems, Inc. | 94.41 Million USD | 107.517% |
| Nephros, Inc. | -1.57 Million USD | -350.603% |
| NovoCure Limited | -207.04 Million USD | 96.572% |
| NEXGEL, Inc. | -3.15 Million USD | -124.802% |
| NEXGEL, Inc. | -3.15 Million USD | -124.802% |
| Singular Genomics Systems, Inc. | -94.82 Million USD | 92.515% |
| OraSure Technologies, Inc. | 53.65 Million USD | 113.227% |
| Pro-Dex, Inc. | 2.12 Million USD | 433.662% |
| Pulse Biosciences, Inc. | -42.21 Million USD | 83.186% |
| Predictive Oncology Inc. | -13.98 Million USD | 49.249% |
| Precision Optics Corporation, Inc. | -2.95 Million USD | -140.464% |
| QuidelOrtho Corporation | -10.1 Million USD | 29.733% |
| Repligen Corporation | 41.57 Million USD | 117.07% |
| Sanara MedTech Inc. | -4.3 Million USD | -64.924% |
| STAAR Surgical Company | 21.34 Million USD | 133.246% |
| Sharps Technology, Inc. | -9.84 Million USD | 27.888% |
| Utah Medical Products, Inc. | 16.63 Million USD | 142.663% |
| DENTSPLY SIRONA Inc. | -132 Million USD | 94.623% |
| Jin Medical International Ltd. | 2.87 Million USD | 346.575% |